MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation (NCT00256776), a randomized phase 3 study. The primary outcome is Median Time to Progression (TTP).

2. Clinical Question

The study was randomized and used a parallel-group design. Its official title describes a comparison in patients progressing or relapsing after autologous transplantation, while the brief summary says eligible patients had responded and later experienced progression or relapse at least one year after transplantation. The trial enrolled 269 participants. The registry lists multiple myeloma as the condition and identifies the European Society for Blood and Marrow Transplantation as sponsor.

The question is specific to this clinical setting and comparison. It is not a general comparison of the regimens across all people with multiple myeloma, nor does the registry record establish how the findings apply to patients outside the described eligibility group. The posted primary results give an estimated median time to progression for each arm and a 95% confidence interval for each median. A statistical comparison between arms, including a hazard ratio or p-value, is not reported in the registry record.

3. Trial Design

This was a phase 3, randomized, open-label, parallel-group study. Participants were assigned to Velcade plus thalidomide plus dexamethasone or thalidomide plus dexamethasone. The record lists no masking, so the trial was not described as blinded. The sponsor was the European Society for Blood and Marrow Transplantation. The registry lists an enrollment of 269 participants: 135.0 in the combination arm and 134.0 in the comparator arm.

The population was adults with multiple myeloma who had undergone at least one autologous stem cell transplantation and later experienced progression or relapse after responding. The brief summary specifies that this occurred at least one year after transplantation. Additional details about eligibility, treatment schedules, dose modifications, and follow-up procedures are not reported in the registry record.

The study began in 2005-07, and primary completion is listed as 2013-12. Its status is terminated. The reason for termination, the timing of the decision, and any consequences for planned enrollment or follow-up are not reported in the registry record. The listed enrollment and arm sizes describe what the record reports, but they do not explain whether the study reached its intended recruitment target; the target and its justification are not reported in the registry record.

The registry identifies median time to progression as the primary outcome, with a timeframe of 3 year. It also lists progression-free survival, overall survival, and response rate as secondary outcomes. The record lists four outcome measures overall, but does not provide a full account of the outcome definitions or analysis procedures. The results available for the primary endpoint are arm-specific medians and confidence intervals; no arm-comparison analysis is posted.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Median Time to Progression (TTP), measured over 3 year.

Time to progression measures the time from a defined starting point until the disease is recorded as progressing. The study summary describes it as the time after treatment until the disease starts to get worse. The registry lists median time to progression in months as the primary endpoint, with a 3 year timeframe. The precise operational definition, including the assessment schedule, progression criteria, and handling of deaths before documented progression, is not reported in the registry record.

A median is the point in the time-to-event distribution at which half of the observed or estimated event-time distribution lies on either side. In a clinical trial, time-to-event methods can incorporate information from participants whose event has not been observed by the end of their available follow-up. The registry record does not describe the censoring rules or the estimation method used for these posted medians, so those details should not be assumed.

Time to progression is useful because it focuses on when worsening is recorded, rather than only whether progression occurred by a single fixed visit. It is distinct from progression-free survival, which is separately listed as a secondary outcome. The registry record does not provide enough detail to establish the exact distinction used in this trial. The posted median estimates describe each arm separately; without a reported comparative analysis, they do not by themselves establish the size or statistical uncertainty of a treatment contrast.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a median time-to-event estimate mean?

Time-to-event outcomes record how long it takes for an event to occur. Here, the event is progression, and the registry reports the median time to progression in months. The median provides a central summary of the event-time distribution. It does not describe the time for every participant, nor does it show the full distribution of progression times. Two groups can have different medians while having overlapping distributions, and the medians alone do not characterize the pattern of events over time.

Time-to-event analysis commonly accommodates participants whose event has not been observed during their recorded follow-up. Such observations are generally treated as censored at the last known time without the event. This is a general explanation, not a description of the trial's actual handling: censoring procedures and the estimation method are not reported in the registry record. The posted results do not include event counts, censoring counts, or survival curves, so those features cannot be assessed from the registry record.

How should the confidence intervals be read?

The 95% confidence intervals are uncertainty intervals around the two reported median estimates. In general, a confidence interval is generated by a statistical procedure designed to produce intervals that cover the underlying quantity at the stated rate over repeated use of that procedure, when its assumptions hold. It is not a guarantee about the particular interval, and it does not mean that a specified proportion of participants had event times within the interval. The record does not name the interval method or its assumptions.

The arm-specific intervals do not constitute a confidence interval for the contrast between treatments. Nor does comparing the intervals provide the same result as a formal hypothesis test. A treatment comparison for time-to-event data may use a hazard ratio or a test based on event times, but neither a hazard ratio nor a test result is reported in the registry record. The record lists no posted analyses for the outcomes, so there is no registered comparative estimate to interpret.

What is randomization intended to do?

In general, random assignment aims to make treatment groups comparable, on average, with respect to measured and unmeasured characteristics at the start of a trial. It supports a causal comparison when allocation is implemented appropriately and the analysis preserves the intended comparison. This trial is listed as randomized, but the sequence-generation and allocation-concealment methods are not reported in the registry record. The record also does not specify the analysis population or whether participants were analyzed according to their assigned arm.

The study is listed as parallel-group and unmasked. In an unmasked trial, participants and study personnel may know the assigned treatment. For an outcome involving assessment of progression, knowledge of allocation can be relevant to assessment and management, although the registry record does not describe the assessment process or safeguards against bias. No claim about the presence or absence of bias can be drawn from the masking entry alone.

What do the planning illustrations represent?

The planning illustrations use the observed effect as a basis for exploring sample-size requirements under stated assumptions. The assumptions include a two-sided significance level of 0.05, equal allocation, a normal approximation, and an effect to detect set as a stated fraction of the observed effect. For time-to-event planning, the calculation is based on a total number of events using the Schoenfeld approach. These are planning illustrations, not evidence of the trial's original design rationale and not observed power. The trial's own sample-size justification and statistical planning assumptions are not reported in the registry record. No sample-size value from the illustrations is repeated in this explanation.

In general, a planning calculation depends on the target effect, variability or event rate, significance threshold, allocation, and analysis method. Changing an assumption can change the number of participants or events required. For a time-to-event outcome, the number of observed events is often central to the precision of a treatment comparison; enrollment alone does not reveal how much event information was available. The registry record does not report the primary endpoint event count or the planned number of events.

Why does over-dispersion matter in some analyses?

General statistical context: over-dispersion occurs when count data vary more than a model assumes. If it is ignored, standard errors can be too small and confidence intervals or tests can appear more precise than warranted. This trial's posted primary endpoint is a time-to-event median, not a count outcome, and the registry record does not report an over-dispersion model. The concept is therefore general background rather than a reported feature of this analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists median time to progression as the primary outcome and three secondary outcomes: progression-free survival, overall survival, and response rate. It also lists four outcome measures overall. Testing or interpreting multiple outcomes can raise multiplicity concerns: when several hypotheses are examined, the chance of at least one apparently notable result can increase unless the analysis plan accounts for the number and relationship of the tests. This is general statistical context, not a claim that this trial used any particular adjustment.

The registry record does not report a multiplicity strategy, a hierarchy of outcomes, or whether secondary outcomes were intended to support confirmatory claims. It lists no posted analyses. Accordingly, there are no posted secondary-outcome estimates or tests to assess, and no adjustment method can be described. The planned statistical analysis plan is not reported in the registry record.

Missing-data handling and analysis populations are also not reported in the registry record. The entry does not specify how participants with incomplete follow-up, missing assessments, or protocol deviations were handled. It does not say whether the primary analysis used all randomized participants, an eligible population, or another analysis set. These details are important because exclusions and missing outcome information can affect both the estimated treatment contrast and its uncertainty.

For time-to-event outcomes, incomplete follow-up is often represented through censoring, but the trial's censoring rules, assumptions, and sensitivity analyses are not reported in the registry record. The record also does not provide the number of participants with missing endpoint information or the number of progression events. Without these details and a posted comparative analysis, the effect of missingness and the robustness of the endpoint result cannot be evaluated from the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: various other saes (23.0%), infection (11.9%), pneumonia (11.1%), pulmonary embolism (4.4%), neuropathy (2.2%).

The serious adverse event summary lists 58 affected participants among 135 at risk in the Thal + Dex + Velcade arm and 45 among 134 at risk in the Thal + Dex arm. These are participant counts in the registry record, not counts of all individual events; a participant may experience more than one event. The record lists zero participants with other adverse events in each arm's corresponding summary field. Death counts are not reported.

The serious-event terms listed include “Various other SAEs” at 23.0%, “Infection” at 11.9%, “Pneumonia” at 11.1%, “Pulmonary Embolism” at 4.4%, “Neuropathy” at 2.2%, and “Renal Failure” at 2.2%. The record does not identify an arm for these term-specific percentages in the summary, so they should not be read as arm-specific rates. The categories and percentages describe the posted safety listing; they do not establish comparative risk.

Interpretation is limited because the registry record does not give event-specific counts by arm, exposure time, severity grading details, or a statistical comparison. The all-cause serious adverse event counts are not enough to determine whether observed differences reflect treatment, follow-up duration, or other factors. These figures are descriptive registry results, not a complete account of safety.

12. What the Result Does, and Does Not, Mean

The primary results are arm-specific median time-to-progression estimates: 19.5 months for Thal + Dex + Velcade and 13.8 months for Thal + Dex. Each estimate has a 95% confidence interval, reported as 16.3 to 22.7 months and 10.0 to 16.4 months, respectively. These values describe the posted endpoint summaries. The registry record does not report a direct statistical comparison, so the medians should not be presented as a tested treatment effect.

The results do not establish how likely an individual participant was to experience progression by a particular time, how the full event-time distributions compared, or whether any difference between arms is statistically distinguishable from chance. A median is not a measure of the experience of every participant. The confidence intervals quantify uncertainty around each median under an unspecified method; they do not provide the uncertainty for a between-arm contrast.

The record does not report a hazard ratio, p-value, event count, or analysis population for the primary endpoint. It also does not provide analyses for the listed secondary outcomes. The status is terminated, but the reason for termination and its relationship to data collection or analysis are not reported in the registry record. Those missing details prevent a fuller assessment of the strength and completeness of the evidence.

The results are specific to the described population: adults with multiple myeloma after autologous transplantation who had responded and later progressed or relapsed. The record does not establish that the findings apply to other patient groups or treatment settings. The results also do not provide enough information to make clinical recommendations. They should be read as a registry report of descriptive endpoint estimates and safety counts, with important comparative and methodological details unavailable.

13. Why This Trial Matters Statistically

This trial illustrates the distinction between reporting an outcome within each randomized arm and reporting a statistical comparison between arms. Median time to progression is available for both groups, together with confidence intervals, but no comparative estimate or test is posted. Readers can describe the reported medians, but cannot recover a valid treatment-effect estimate simply by treating the two arm summaries as if they were a direct analysis.

The example also shows why the method behind an interval matters. Confidence intervals around separate medians answer questions about uncertainty in those individual estimates; the main clinical comparison concerns the difference between assigned strategies. A suitable comparative analysis would need to account for the time-to-event structure and the study's analysis plan. That plan and its results are not reported in the registry record.

Randomized allocation is a key design feature, yet the registry record's incomplete information about concealment, outcome assessment, censoring, analysis populations, and missing data leaves important parts of the evidence pathway undescribed. The unmasked designation is also relevant context when interpreting a progression endpoint, though the record does not document how progression was assessed.

Finally, enrollment and a terminated status do not, by themselves, reveal whether the trial was adequately powered or why it ended. Planning illustrations based on observed effects are not substitutes for a prespecified sample-size rationale, and they are not observed power. This record therefore offers a useful lesson in separating descriptive results from the inferential evidence needed to evaluate a randomized comparison.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific details needed for a complete interpretation are not reported in the registry record. The reason for termination is not stated, and the relationship between termination and the planned enrollment, follow-up, or analysis is unknown. Although enrollment is listed as 269, the target enrollment and sample-size justification are not reported.

The registry gives arm-specific primary endpoint medians and confidence intervals but no comparative analysis. It does not report a hazard ratio, p-value, event count, survival curve, or analysis population. The method used to calculate the median and confidence intervals, the progression criteria, assessment schedule, censoring rules, and handling of death before progression are also not reported in the registry record. As a result, the precision and assumptions behind the endpoint estimates cannot be fully assessed.

The record lists secondary outcomes but does not post their analyses. It does not describe a multiplicity plan, missing-data procedures, sensitivity analyses, or whether analyses followed randomized assignment. Further design details, including allocation concealment and treatment schedules, are not reported. The safety summary gives serious adverse event counts and a list of event terms, but does not provide arm-specific counts for each listed term or a comparative safety analysis.

These limitations concern what the registry record documents; they do not establish that the trial lacked procedures or analyses. They mean those features cannot be evaluated from the posted record. In particular, the arm medians should remain descriptive in the absence of a reported between-arm analysis.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation — NCT00256776.
• Registry record last updated 2021-10-18; status last verified 2021-09.
• Results first posted 2021-10-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00256776 is a phase 3 randomized, unmasked, parallel-group trial sponsored by the European Society for Blood and Marrow Transplantation. It enrolled 269 adults with multiple myeloma in the setting of progression or relapse after autologous transplantation. The record lists study start as 2005-07, primary completion as 2013-12, and status as terminated.

The primary outcome is median time to progression in months, with a 3 year timeframe. Posted medians are 19.5 months for Thal + Dex + Velcade and 13.8 months for Thal + Dex, each with a 95% confidence interval. No comparative analysis is posted in the registry record. Three secondary outcomes are listed, but their results are not posted. The serious adverse event summary reports 58 affected participants in the combination arm and 45 in the comparator arm. The reason for termination and several key analysis details are not reported in the registry record.